263 related articles for article (PubMed ID: 9796989)
1. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
[TBL] [Abstract][Full Text] [Related]
4. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
5. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
Xu FJ; Boyer CM; Bae DS; Wu S; Greenwald M; O'Briant K; Yu YH; Mills GB; Bast RC
Int J Cancer; 1994 Oct; 59(2):242-7. PubMed ID: 7927925
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
FitzGerald DJ; Bjorn MJ; Ferris RJ; Winkelhake JL; Frankel AE; Hamilton TC; Ozols RF; Willingham MC; Pastan I
Cancer Res; 1987 Mar; 47(5):1407-10. PubMed ID: 3493065
[TBL] [Abstract][Full Text] [Related]
7. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
8. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
9. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
Deshane J; Cabrera G; Grim JE; Siegal GP; Pike J; Alvarez RD; Curiel DT
Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells.
Wiechen K; Karaaslan S; Turzynski A; Dietel M
Br J Cancer; 1999 Nov; 81(5):790-5. PubMed ID: 10555747
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model.
Leonard JE; Johnson DE; Shawler DL; Dillman RO
Cancer Res; 1988 Sep; 48(17):4862-7. PubMed ID: 3261627
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
Yu D; Liu B; Tan M; Li J; Wang SS; Hung MC
Oncogene; 1996 Sep; 13(6):1359-65. PubMed ID: 8808711
[TBL] [Abstract][Full Text] [Related]
13. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
Chen X; Yeung TK; Wang Z
Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
15. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
16. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
17. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
18. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor.
Vollmar AM; Banker DE; Mendelsohn J; Herschman HR
J Cell Physiol; 1987 Jun; 131(3):418-25. PubMed ID: 3496342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]